MDG1.F stock surges 59.5% on May 7 as Medigene AG rallies on XETRA

MDG1.F stock surged 59.5% on May 7, 2026, reaching €0.0386 on the XETRA exchange in Germany. Medigene AG, the Munich-based biotechnology company, delivered one of the day’s strongest intraday performances as trading volume jumped to 12,602 shares, significantly above the 3,280-share average. The stock opened at €0.0232 and climbed to a session high of €0.0406, marking a dramatic reversal from recent weakness. While Medigene AG remains in liquidation of its remaining assets after winding down T-cell therapy development, today’s rally reflects renewed investor interest in the MDG1.F stock price action on XETRA.

MDG1.F Stock Price Action and Intraday Movement

MDG1.F stock opened Thursday at €0.0232 and climbed steadily throughout the session. The stock reached a day high of €0.0406, delivering a 59.5% gain from the previous close of €0.0242. This represents a €0.0144 absolute price increase, marking the strongest single-day performance in recent weeks.

Volume and Trading Intensity

Trading volume surged to 12,602 shares, nearly 4 times the average daily volume of 3,280 shares. This 1.48x relative volume spike indicates heightened investor participation and suggests renewed attention on the MDG1.F stock ticker. The elevated activity reflects both retail and institutional interest in the biotechnology name despite its liquidation status.

Technical Indicators and Market Sentiment

Technical analysis reveals mixed signals for MDG1.F stock. The Relative Strength Index (RSI) sits at 50.36, indicating neutral momentum without overbought or oversold conditions. The Average True Range (ATR) of €0.01 shows modest volatility, while the Commodity Channel Index (CCI) at 45.80 suggests building momentum.

Trading Activity and Liquidation Dynamics

The Money Flow Index (MFI) reached 75.94, signaling strong buying pressure and potential accumulation by institutional investors. The Awesome Oscillator remains flat at 0.00, suggesting consolidation before potential directional moves. Despite the company’s liquidation phase, technical strength in MDG1.F stock indicates traders are positioning for continued upside momentum through the remainder of May.

Fundamental Metrics and Valuation Context

Medigene AG trades at an extremely depressed valuation relative to book value. The price-to-book ratio stands at just 0.0163, meaning the stock trades at less than 2% of tangible book value per share of €1.63. The market capitalization of €392,020 reflects the company’s micro-cap status on XETRA.

Financial Position During Liquidation

The company maintains a current ratio of 2.53, indicating adequate short-term liquidity to manage ongoing operations and asset liquidation. Cash per share totals €1.29, providing a cushion above the current stock price. However, the negative earnings per share of -€1.21 and negative return on equity of -55.7% underscore the company’s unprofitable status. Track MDG1.F on Meyka for real-time updates on liquidation progress and asset sales.

Year-to-Date Performance and Long-Term Decline

While MDG1.F stock gained 59.5% today, the broader picture reveals severe long-term deterioration. Year-to-date, the stock is up just 6.4%, but over the past year it has declined 67.2%. The three-year loss stands at 99.2%, and the five-year decline reaches 99.6%, reflecting the company’s transition from active drug development to asset liquidation.

Historical Context and Recovery Prospects

The year high of €0.212 versus the current price of €0.0386 shows the stock trades at just 18% of its 52-week peak. The year low of €0.0126 means today’s price represents a 206% recovery from the lowest point. Meyka AI rates MDG1.F with a grade of C+ with a HOLD suggestion, reflecting the high-risk nature of investing in a company undergoing liquidation.

Final Thoughts

MDG1.F stock delivered a powerful 59.5% intraday rally on May 7, 2026, capturing investor attention despite Medigene AG’s ongoing liquidation. The surge to €0.0386 on elevated volume signals renewed interest in the micro-cap biotechnology name trading on XETRA. While technical indicators show building momentum and the company maintains adequate liquidity with a 2.53 current ratio, fundamental challenges persist. The negative earnings, depressed valuation at 0.0163x book value, and long-term decline of 99.6% over five years underscore the speculative nature of this position. Investors should recognize that MDG1.F stock remains a high-risk liquidation play suitable o…

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.